The PPARβ/δagonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension

PLoS ONE

Volumn 5, Issue 3, 2010, Pages

  Harrington, Louise S ^a   Moreno, Laura ^a   Reed, Anna ^a   Wort, Stephen J ^b   Desvergne, Béatrice ^c   Garland, Christopher ^d   Zhao, Lan ^e   Mitchell, Jane A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

[4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; CYCLIC AMP; CYCLIC GMP; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROSTACYCLIN RECEPTOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA PROTEIN, MOUSE; THIAZOLE DERIVATIVE;

ANIMAL MODEL; AORTA; ARTICLE; CONTROLLED STUDY; HEART HYPERTROPHY; HEART VENTRICLE PRESSURE; HYPERPOLARIZATION; HYPOXIA; LUNG BLOOD VESSEL; MALE; MOUSE; NONHUMAN; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; VASODILATATION; ANIMAL; ANOXIA; CARDIOMEGALY; DRUG EFFECT; DRUG POTENTIATION; LUNG; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; TRANSGENIC MOUSE; VASCULARIZATION; WISTAR RAT;

ANIMALIA; MUS; RATTUS;

ADMINISTRATION, ORAL; ANIMALS; ANOXIA; CARDIOMEGALY; HYPERTENSION, PULMONARY; LUNG; MALE; MICE; MICE, TRANSGENIC; PPAR DELTA; PPAR-BETA; RATS; RATS, WISTAR; RHO GTP-BINDING PROTEINS; RHOA GTP-BINDING PROTEIN; THIAZOLES;

EID: 77949663350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009526     Document Type: Article

References (33)

1. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, et al. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30: 2493-2537.
2. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, et al. (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115: 343-349.
3. Wort SJ, Woods M, Warner TD, Evans TW, Mitchell JA (2001) Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling. Am J Respir Cell Mol Biol 25: 104-110.
4. Humbert M, Sitbon O, Simonneau G (2004) Treatment of pulmonary arterial hypertension. N Engl J Med 351: 1425-1436.
5. McLaughlin VV, Shillington A, Rich S (2002) Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106: 1477-1482.
6. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, et al. (2002) Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40: 780-788.
7. Bishop-Bailey D, Pepper JR, Haddad EB, Newton R, Larkin SW, et al. (1997) Induction of cyclooxygenase-2 in human saphenous vein and internal mammary artery. Arterioscler Thromb Vasc Biol 17: 1644-1648.
8. Mitchell JA, Ali F, Bailey L, Moreno L, Harrington LS (2008) Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium. Exp Physiol 93: 141-147.
9. Wise H (2003) Multiple signalling options for prostacyclin. Acta Pharmacol Sin 24: 625-630.
10. Ali FY, Egan K, FitzGerald GA, Desvergne B, Wahli W, et al. (2006) Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol 34: 242-246.
11. Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark M, et al. (2006) Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta. Faseb J 20: 326-328.
12. Crossno JT Jr, Garat CV, Reusch JE, Morris KG, Dempsey EC, et al. (2007) Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 292: L885-897.
13. Matsuda Y, Hoshikawa Y, Ameshima S, Suzuki S, Okada Y, et al. (2005) [Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats]. Nihon Kokyuki Gakkai Zasshi 43: 283-288.
14. Hart CM (2008) The Role of PPARgamma in pulmonary vascular disease. J Investig Med 56: 518-521.
15. Harrington LS, Carrier MJ, Gallagher N, Gilroy D, Garland CJ, et al. (2007) Elucidation of the temporal relationship between endothelial-derived NO and EDHF in mesenteric vessels. Am J Physiol Heart Circ Physiol 293: H1682-1688.
16. Cheng Y, Austin S, Rocca B, Koller B, Coffman T, et al. (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296: 539-541.
17. Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, et al. (2001) Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 15: 3263-3277.
18. Cogolludo A, Moreno L, Frazziano G, Moral-Sanz J, Menendez C, et al. (2009) Activation of neutral sphingomyelinase is involved in acute hypoxic pulmonary vasoconstriction. Cardiovasc Res 82: 296-302.
19. Mulvany MJ, Halpern W (1977) Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41: 19-26.
20. Dora KA, Gallagher NT, McNeish A, Garland CJ (2008) Modulation of endothelial cell KCa3.1 channels during endothelium-derived hyperpolarizing factor signaling in mesenteric resistance arteries. Circ Res 102: 1247-1255.
21. Haskova Z, Hoang B, Luo G, Morgan LA, Billin AN, et al. (2008) Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARbeta/delta ligand GW0742. Inflamm Res 57: 314-321.
22. Guignabert C, Izikki M, Tu LI, Li Z, Zadigue P, et al. (2006) Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98: 1323-1330.
23. Weissmann N, Hackemack S, Dahal BK, Pullamsetti SS, Savai R, et al. (2009) The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol 297: L658-665.
24. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, et al. (2001) Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104: 424-428.
25. Belvisi MG, Mitchell JA (2009) Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. Br J Pharmacol 158: 994-1003.
26. Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, et al. (2003) Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 302: 453-457.
27. Akbiyik F, Ray DM, Gettings KF, Blumberg N, Francis CW, et al. (2004) Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 104: 1361-1368.
28. Ali FY, Armstrong PC, Dhanji AR, Tucker AT, Paul-Clark MJ, et al. (2009) Antiplatelet actions of statins and fibrates are mediated by PPARs. Arterioscler Thromb Vasc Biol 29: 706-711.
29. Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. (2009) Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 54: S78-84.
30. Sznaidman ML, Haffner CD, Maloney PR, Fivush A, Chao E, et al. (2003) Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)-synthesis and biological activity. Bioorg Med Chem Lett 13: 1517-1521.
31. Ali FY, Hall MG, Desvergne B, Warner TD, Mitchell JA (2009) PPAR{beta}/{delta} Agonists Modulate Platelet Function via a Mechanism Involving PPAR Receptors and Specific Association/Repression of PKC{alpha}. Arterioscler Thromb Vasc Biol.
32. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, et al. (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 34: 1219-1263.
33. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, et al. (1995) Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 79: 2122-2131.